RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Molecular Partners Stock

Molecular Partners P/S 2025

Molecular Partners P/S

17.79

Ticker

MOLN.SW

ISIN

CH0256379097

WKN

A12DEH

As of Jan 2, 2025, Molecular Partners's P/S ratio stood at 17.79, a -14.27% change from the 20.75 P/S ratio recorded in the previous year.

The Molecular Partners P/S history

Molecular Partners Aktienanalyse

What does Molecular Partners do?

Molecular Partners AG is a biopharmaceutical company based in Zurich, specializing in the research and development of novel therapies in the fields of cancer and ophthalmology. The company was founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETHZ) and has since made significant progress in drug research and development. The business model of Molecular Partners is based on the development of so-called DARPins (Designed Ankyrin Repeat Proteins). DARPins are artificially created protein molecules that can be used as highly specific binding partners in drug research and development. Due to their modular structure and flexibility, DARPins can bind to a variety of target molecules, thus serving as a basis for the development of new therapies. The various divisions of Molecular Partners focus on the development of therapies in the areas of cancer and ophthalmology. In the field of cancer, the company has a number of promising drug candidates based on DARPins in preclinical and clinical development. One of the most promising candidates is MP0250, a bispecific DARPin that targets two targets and is intended to suppress cancer cell activity. In the field of ophthalmology, Molecular Partners is developing therapies for the treatment of retinal diseases and other eye diseases. One of the most promising candidates in this area is Abicipar, an anti-VEGF DARPin that can be used to treat wet age-related macular degeneration and other retinal diseases. Abicipar has already shown promising results in clinical trials and is currently being submitted for approval to US and European regulatory authorities. Molecular Partners has formed partnerships with leading pharmaceutical and biotech companies such as Amgen, Allergan, Novartis, and Nestlé Health Science to support the development and commercialization of their drug candidates. In addition, the company has entered into a number of licensing and collaboration agreements with other companies to advance the development of new therapies. Overall, Molecular Partners has made significant progress in the development of novel therapies in the fields of cancer and ophthalmology in recent years. The company has developed a unique platform technology on which a variety of therapies can be based, tailored to the specific needs of patients. With its strong partnerships and pipeline of drug candidates, Molecular Partners is well positioned to continue growing and developing new treatment options for patients in the coming years. Molecular Partners ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Molecular Partners's P/S Ratio

Molecular Partners's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Molecular Partners's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Molecular Partners's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Molecular Partners’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Molecular Partners stock

What is the price-to-earnings ratio of Molecular Partners?

The price-earnings ratio of Molecular Partners is currently 17.79.

How has the price-earnings ratio of Molecular Partners changed compared to last year?

The price-to-earnings ratio of Molecular Partners has increased by -14.27% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Molecular Partners high compared to other companies?

Yes, the price-to-earnings ratio of Molecular Partners is high compared to other companies.

How does an increase in the price-earnings ratio of Molecular Partners affect the company?

An increase in the price-earnings ratio of Molecular Partners would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Molecular Partners affect the company?

A decrease in the price-earnings ratio of Molecular Partners would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Molecular Partners?

Some factors that influence the price-earnings ratio of Molecular Partners are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Molecular Partners pay?

Over the past 12 months, Molecular Partners paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Molecular Partners is expected to pay a dividend of 0 CHF.

What is the dividend yield of Molecular Partners?

The current dividend yield of Molecular Partners is .

When does Molecular Partners pay dividends?

Molecular Partners pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Molecular Partners?

Molecular Partners paid dividends every year for the past 0 years.

What is the dividend of Molecular Partners?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Molecular Partners located?

Molecular Partners is assigned to the 'Health' sector.

Wann musste ich die Aktien von Molecular Partners kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Molecular Partners from 1/2/2025 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 1/2/2025.

When did Molecular Partners pay the last dividend?

The last dividend was paid out on 1/2/2025.

What was the dividend of Molecular Partners in the year 2024?

In the year 2024, Molecular Partners distributed 0 CHF as dividends.

In which currency does Molecular Partners pay out the dividend?

The dividends of Molecular Partners are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Molecular Partners

Our stock analysis for Molecular Partners Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Molecular Partners Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.